ETFChannel.com
ARWR Description — Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of RNA chemistries and several modes of delivery, Co.'s therapies trigger the RNA interference (RNAi) mechanism to induce knockdown of target genes. Co. is focused on developing drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. Co.'s pipeline includes, among others, ARO-AAT, a candidate for the treatment of liver disease, and ARO-APOC3, which is designed to reduce production of Apolipoprotein C-III, a component of triglyceride rich lipoproteins.

Company Name: 
Arrowhead Pharmaceuticals Inc
Website: 
www.arrowheadpharmaceuticals.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding ARWR: 
45
Total Market Value Held by ETFs: 
$496,497,334
Total Market Capitalization: 
$2,970,000,000
% of Market Cap. Held by ETFs: 
16.72%
 ETF   ARWR Weight   ARWR Amount 
 IJH   0.23%   $82,580,351         
 VTI   0.01%   $78,601,419         
 VB   0.10%   $71,392,119         
 IWM   0.20%   $68,543,478         
 VXF   0.07%   $41,900,059         
 VBK   0.20%   $41,776,273         
 IWO   0.36%   $25,798,447         
 IBB   0.38%   $25,410,550         
 IJK   0.41%   $22,033,482         
 VHT   0.07%   $6,544,133         
List of all 45 ETFs holding ARWR »
Quotes delayed 20 minutes

Buy (3.25 out of 4)
52nd percentile
(ranked higher than approx. 52% of all stocks covered)

Analysts Forecast:
ARWR Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding ARWR | Arrowhead Pharmaceuticals Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2020, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.